Circulating Bacterial DNA as a Novel Blood-Based Biomarker in Type 2 Diabetes Mellitus (DM2): Results from the PROMOTERA Study
International Journal of Molecular Sciences · 08.07.2025 · 26 (14) · 6564
DOI: 10.3390/ijms26146564 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.07.2025. Verfasst von Robertina Giacconi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Technology Center for Aging Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) and Istituto Nazionale di Ricerca e Cura A…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, DNA, Bacterial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Health Ministry with PROMOTERA project, Next Generation EU, in the context of the National Recovery and Resilience Plan, Next Generation EU.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Blood bacterial DNA (BB-DNA) has been identified as a novel biomarker for metabolic dysfunction, yet its relationship with epigenetic features in type 2 diabetes mellitus (DM2) patients remains largely unexplored. This study investigated the relationship between BB-DNA and epigenetic, inflammatory, and aging-related markers in 285 elderly both with and without DM2. BB-DNA levels were higher in DM2 patients than in non-diabetic subjects, with the highest levels in those with severe renal impairment. BB-DNA showed a positive association with plasma IL-1β, linking bacterial DNA to systemic inflammation. Epigenetic analysis revealed a negative correlation between BB-DNA and DNA methylation-based leukocyte telomere length, suggesting accelerated aging in DM2. Additionally, BB-DNA was positively associated with DNAm-based biological age estimators, particularly DNAmPhenoAge and DNAmAge Skin Blood Clock. BB-DNA also correlated with DNAmVEGFA and DNAmCystatin C, key markers of diabetic nephropathy and vascular dysfunction. Furthermore, BB-DNA levels were associated with hypomethylation of genes involved in inflammation (e.g., IL1β, TNFα, IFNγ), cellular senescence (p16, p21, TP53), and metabolic regulation (e.g., IGF1, SREBF1, ABCG1, PDK4). These associations suggest that increased BB-DNA may reflect and potentially promote a pro-inflammatory and pro-senescent epigenetic profile in DM2. Importantly, many of these associations remained significant after adjusting for diabetes status, supporting BB-DNA as a robust biomarker across clinical subgroups. These findings provide new insights into the relationship between BB-DNA, inflammation, and epigenetic aging in DM2, highlighting BB-DNA as a potential biomarker for disease progression and complications, particularly in relation to renal dysfunction and systemic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Technology Center for Aging Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) and Istituto Nazionale di Ricerca e Cura Anziani (INRCA), 60127 Ancona, Italy.
- Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, Italy.
- Department of Clinical and Molecular Sciences, Disclimo, Università Politecnica delle Marche, 60127 Ancona, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
- Bioinformatics and Statistical Genomics Unit, Istituto Auxologico Italiano IRCCS, 20095 Cusano Milanino, Italy.
- Unit of Geriatric Pharmacoepidemiology and Biostatistics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) and Istituto Nazionale di Ricerca e Cura Anziani (INRCA), 60124 Ancona, Italy.
ORCID-Profile: Robertina Giacconi, Patrizia D'Aquila, Luciano Calzari, Carlo Fortunato, Gretta Veronica Badillo Pazmay, Mirko Di Rosa, Giuseppe Pelliccioni, Anna Rita Bonfigli, Roberta Galeazzi, Giuseppe Passarino, Dina Bellizzi, Francesco Piacenza
Förderung
- Italian Health Ministry with PROMOTERA project
- Next Generation EU, in the context of the National Recovery and Resilience Plan
- Next Generation EU
- Gruppo Baffa (Sadel Spa, Sadel San Teodoro srl, Sadel CSsrl, Casa di Cura Madonna dello Scoglio, AGI srl, Casa di Cura Villa del Rosario srl, Savelli Hospital…
Zitieren
APA
Giacconi, R., D'Aquila, P., Olivieri, F., Gentilini, D., Calzari, L., Fortunato, C., Badillo Pazmay, G. V., Di Rosa, M., Sena, G., De Rose, E., Cherubini, A., Sarzani, R., Antonicelli, R., Pelliccioni, G., Bonfigli, A. R., Galeazzi, R., Lattanzio, F., Passarino, G., Bellizzi, D., & Piacenza, F. (2025). Circulating Bacterial DNA as a Novel Blood-Based Biomarker in Type 2 Diabetes Mellitus (DM2): Results from the PROMOTERA Study. International Journal of Molecular Sciences, 26(14), 6564. https://doi.org/10.3390/ijms26146564
Vancouver
Giacconi R, D'Aquila P, Olivieri F, Gentilini D, Calzari L, Fortunato C, et al. Circulating Bacterial DNA as a Novel Blood-Based Biomarker in Type 2 Diabetes Mellitus (DM2): Results from the PROMOTERA Study. International Journal of Molecular Sciences. 2025;26(14):6564. doi:10.3390/ijms26146564
BibTeX
@article{Giacconi2025,
author = {Giacconi, Robertina and D'Aquila, Patrizia and Olivieri, Fabiola and Gentilini, Davide and Calzari, Luciano and Fortunato, Carlo and Badillo Pazmay, Gretta Veronica and Di Rosa, Mirko and Sena, Giada and De Rose, Elisabetta and Cherubini, Antonio and Sarzani, Riccardo and Antonicelli, Roberto and Pelliccioni, Giuseppe and Bonfigli, Anna Rita and Galeazzi, Roberta and Lattanzio, Fabrizia and Passarino, Giuseppe and Bellizzi, Dina and Piacenza, Francesco},
title = {Circulating Bacterial DNA as a Novel Blood-Based Biomarker in Type 2 Diabetes Mellitus (DM2): Results from the PROMOTERA Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {14},
pages = {6564},
doi = {10.3390/ijms26146564}
}
EUVIMED